OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
Arndt Vogel, Anna Saborowski, Patrick Wenzel, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 8, pp. 734-744
Open Access | Times Cited: 14
Arndt Vogel, Anna Saborowski, Patrick Wenzel, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 8, pp. 734-744
Open Access | Times Cited: 14
Showing 14 citing articles:
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 1
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 1
Maintenance chemotherapy in biliary tract tumours in the era of immuno-chemotherapy
Ángela Lamarca, Jorge Adeva, I. Ales Díaz, et al.
ESMO Gastrointestinal Oncology (2025) Vol. 7, pp. 100116-100116
Closed Access
Ángela Lamarca, Jorge Adeva, I. Ales Díaz, et al.
ESMO Gastrointestinal Oncology (2025) Vol. 7, pp. 100116-100116
Closed Access
Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma
C. O'Donnell, Umair Majeed, Michael Rutenberg, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 82-82
Open Access
C. O'Donnell, Umair Majeed, Michael Rutenberg, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 82-82
Open Access
Update for: New developments in systemic therapy for advanced biliary tract cancer
Chigusa Morizane, Makoto Ueno, Masafumi Ikeda, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
Chigusa Morizane, Makoto Ueno, Masafumi Ikeda, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
How I Treat Advanced Biliary Cancer
Arathi Mohan, Vaibhav Sahai
Advances in Oncology (2025)
Closed Access
Arathi Mohan, Vaibhav Sahai
Advances in Oncology (2025)
Closed Access
IDHIRA: a prospective, observational study on ivosidenib in patients with IDH1 R132-mutated advanced cholangiocarcinoma
Marlies Michl, Nora Hagemeyer, M. Looß, et al.
Future Oncology (2025), pp. 1-8
Open Access
Marlies Michl, Nora Hagemeyer, M. Looß, et al.
Future Oncology (2025), pp. 1-8
Open Access
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024
Jennifer Leigh, Atique U. Ahmed, F. Aubin, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 175-175
Open Access
Jennifer Leigh, Atique U. Ahmed, F. Aubin, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 175-175
Open Access
Risk comparison of adverse reactions between gemcitabine monotherapy and gemcitabine combined with albumin-bound paclitaxel in pancreatic cancer: insights from the FDA Adverse Event Reporting System (FAERS) database
Puen Jiang, Kezhen Zong, Dadi Peng, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
Puen Jiang, Kezhen Zong, Dadi Peng, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials
Changhoon Yoo, Anna Saborowski, Jaewon Hyung, et al.
Journal of Hepatology (2025)
Open Access
Changhoon Yoo, Anna Saborowski, Jaewon Hyung, et al.
Journal of Hepatology (2025)
Open Access
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine
Cha Len Lee, Anna Saborowski, Arndt Vogel
Expert Opinion on Pharmacotherapy (2024)
Closed Access
Cha Len Lee, Anna Saborowski, Arndt Vogel
Expert Opinion on Pharmacotherapy (2024)
Closed Access
New perspectives in biliary tract cancers
Thorsten Oliver Goetze, Christoph Roderburg, Felix W. Friedrich, et al.
ESMO Gastrointestinal Oncology (2024) Vol. 5, pp. 100092-100092
Open Access
Thorsten Oliver Goetze, Christoph Roderburg, Felix W. Friedrich, et al.
ESMO Gastrointestinal Oncology (2024) Vol. 5, pp. 100092-100092
Open Access
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets
Linde Kehmann, Markus S. Jördens, S Loosen, et al.
ESMO Open (2024) Vol. 9, Iss. 10, pp. 103706-103706
Open Access
Linde Kehmann, Markus S. Jördens, S Loosen, et al.
ESMO Open (2024) Vol. 9, Iss. 10, pp. 103706-103706
Open Access
Reply to Y. Liang et al
Lukas Perkhofer, Thomas Seufferlein, Anna Fichtl, et al.
Journal of Clinical Oncology (2024)
Closed Access
Lukas Perkhofer, Thomas Seufferlein, Anna Fichtl, et al.
Journal of Clinical Oncology (2024)
Closed Access
